Abstract #2382

Impact of MRI protocol compliance on the prediction of pCR in the I-SPY 2 neoadjuvant breast cancer trial

Natsuko Onishi¹, Li Wen¹, Jessica Gibbs¹, Ella F. Jones¹, Lisa J. Wilmes¹, Alex Nguyen¹, Vignesh Arasu¹, Bonnie N. Joe¹, Laura J. Esserman², The I-SPY 2 Investigator Network³, David C. Newitt¹, and Nola M. Hylton¹

¹Department of Radiology & Biomedical Imaging, University of California, San Francisco, San Francisco, CA, United States, ²Department of Surgery, University of California, San Francisco, San Francisco, CA, United States, ³Quantum Leap Healthcare Collaborative, San Francisco, CA, United States

In the I-SPY2 breast cancer trial, functional tumor volume (FTV, a quantitative measure of tumor burden derived from dynamic contrast-enhanced MRI) serves as a marker used for patient randomization and estimation of predictive probabilities for pathologic complete response (pCR). This retrospective study investigated the impact of MRI protocol compliance on prediction of pCR using FTV at four time points during neoadjuvant chemotherapy. FTV with compliant image quality factors tended to show higher AUC than that with non-compliant factors. This tendency was most prominent in percent change of FTV from baseline at early-treatment (3 weeks after treatment initiation) and inter-regimen.

This abstract and the presentation materials are available to members only; a login is required.

Join Here